Background: Biomarkers are detected during bone formation and resorption associated with the dynamics of bone metabolism and are gaining importance as preferential indicators of bone healing in comparison with conventional methodologies. Current literature suggests that the usage of bone turnover markers for monitoring bone regeneration in association with biomaterials is limited.
periodontal therapy is to eliminate infection and inflammation, restore periodontal soft tissues, and stabilize the alveolar bone. 1 A stable and healthy alveolar bone is necessary for the long-term functioning of dental implants (DI) and their corresponding superstructures. Guided tissue regeneration (GTR) and guided bone regeneration (GBR) aim to reconstruct periodontal soft tissues and regenerate damaged alveolar bone respectively, through the application of different biomaterials (i.e., membranes, bone substitutes) over an osseous defect. 2 Guided bone regeneration is capable of regaining the contour of the diseased dental alveolar ridge 3 and is also useful for socket preservation, 4 thereby helping in the replacement of missing teeth with DI. 5 As a result of its predictable benefits, GBR has become an integral part of periodontal therapy and DI rehabilitation procedures. 6 In clinical practice, bone regeneration and healing are primarily evaluated by radiographic imaging in addition to bone sounding and histopathological evaluation of biopsied bone. 7 There are several reported limitations to the traditional diagnostic methods which make optimal estimation of the success of GBR difficult. Moreover, radiographic determination of bone healing is highly subjective and can prove difficult to diagnose during the early phases of bone regeneration. 8 The advent of bonebiomarkers as an assessment tool with the primary objective of monitoring early bone regeneration is therefore promising. Bone-biomarkers, when evaluated objectively, serve as an indicator of not only the normal bone healing process, but also pathogenic processes and responses to therapeutic intervention. Evidence-based literature acknowledges bone-biomarkers as a noninvasive, convenient, and relatively inexpensive indicator for monitoring bone metabolism and early healing. 9 Bone-biomarkers indicative of metabolic processes include collagen breakdown products such as hydroxyproline, collagen crosslinks and telopeptides in addition to noncollagenous matrix proteins such as bone sialoprotein (BSP), osteoclast-specific enzyme like tartrate-resistant acid phosphatase (TRAP) and cathepsin K. On the contrary, biomarkers such as alkaline phosphatase (ALP), osteoblast-specific proteins like osteocalcin (OCN) and osteopontin (OPN), and type I collagen (COL-1, byproduct of collagen neosynthesis) are secreted during different stages of bone formation. 10 Similarly, bone-biomarkers are formed as byproducts of bone cell activity during the different phases of bone healing, 11 which begins with early bone cell reactions, followed by bone matrix deposition, and, finally, matrix mineralization and remodeling. 12 The utility of identifying bone-biomarkers during bone healing not only enhances the accuracy of assessing bone regeneration, but would also allow early detection of successful outcomes. 13 Elevated levels of bone-biomarkers have been clinically detected in the serum and saliva, wherein their quantitative evaluation has proved to be of diagnostic and prognostic significance. 14, 15 In spite of their extensive clinical implications, only limited studies have demonstrated the utility of biomarkers as a diagnostic measure of bone regeneration. Even within the limited evidence available in the literature, biomarker evaluation has been considered only as a secondary tool of assessment of bone regeneration, while histopathology, histomorphometry, and radiographic imaging, or a combination of the above has remained the primary choice. Therefore, the objective of this systematic review of literature was to evaluate the role of bone-biomarkers in independently predicting bone regeneration following implantation of various biomaterials.
MATERIALS AND METHODS

Focused Question
The present review of the literature was conducted with the focused question: "Are bone-biomarkers capable of independently predicting bone regeneration following implantation of different bone biomaterials in an osseous defect?"
Literature Search and Selection Criteria
A systematic review of published studies evaluating bone-biomarkers during bone regeneration from 1980 until and including January 2017 was conducted. An electronic search was organized in PubMed (MEDLINE) database using the terms "bone-biomarkers," "bone regeneration," and "bone biomaterials" in combination with the Boolean operators "AND" and "OR." 16 Following this, a manual search was performed additionally by screening the bibliographies of relevant retrieved articles and adding free-text words from titles or abstracts to identify potentially pertinent articles. All articles retrieved through the literature search were imported into a bibliographic referencing software program (EndNote X7), and duplicate references were identified and removed. In order to eliminate selection bias, two independent reviewers (SA, AA), who were calibrated for intraobserver and interobserver reliability and agreement screened the relevant titles, abstracts, and full texts, and the articles for final review were selected according to preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines, 17 based on the following inclusion and exclusion criteria.
Inclusion Criteria
• Original research articles published in the English language, based on human clinical trials, case-control studies, cohort studies, case series, and case reports in addition to in vivo animal studies related to the usage of bone-biomarkers for evaluating bone regeneration in osseous defects following placement of biomaterials.
• Articles presenting data pertaining to the model used for research, biomaterials used for bone regeneration, bone-biomarkers evaluated, and the methods used for their assay, along with information relating to followup examination protocols.
Exclusion Criteria
Studies with insufficient information, ex vivo and in vitro researches, case reports, reviews and, technical and personal communications.
Data Extraction and Study Characteristics
Data extraction from all included studies was independently performed and verified by the two reviewers. When both reviewers agreed on exclusions, the reasons for exclusion were recorded. Any remaining disagreements were resolved by consensus or discussion, if necessary. The data extraction process was guided by a data extraction sheet that specified the relevant study characteristics, including author, year of publication, study design, information related to bone regeneration procedures (type of implanted biomaterials, anatomical site, and healing time), data for the biomarkers assessment (type and assay methods), and reported biomarkers' outcomes that evaluate bone formation in relation to the implanted biomaterials.
RESULTS
A total of 443 studies were identified through electronic searching of the PubMed (MEDLINE) database. Screening the titles and abstracts of the identified studies led to the selection of 117 full-text manuscripts, which were scrutinized and narrowed down to 62 studies, based on their relevance to the focused question of the present review. Following exclusion of duplicates, 41 studies fulfilled the inclusion criteria and were finally considered for systematic review (Flow Chart 1). The selected studies were reviewed by both the authors for the purpose of data extraction, and interpretation. A detailed characterization of the study objectives, study subjects (human/animal model), type of defect investigated along with implanted bone biomaterial, and the biomarkers evaluated under the specified time period for desirable outcomes is elaborated in Table 1 .
Description of Experimental Methods
Majority of the reviewed studies used animal models in their research, while only four studies [18] [19] [20] [21] were based on human clinical models. While two out of the four human studies, evaluated the role of biomarkers for assessment of bone regeneration, 19, 21 one of the studies was based on the assessment of bone formation along with GTR 20 and
another study was based on osseointegration and new bone formation around titanium DI. 18 Heterogeneity in terms of the protocols of biomaterial implantation and their respective follow-up periods were widely observed among the reviewed studies. Interestingly, the shortest period of biomaterial implantation, which was evaluated, was 1 day, 22, 23 whereas the maximum period of biomaterial implantation was observed to be 16 weeks. 18 Several bone biomaterials were investigated (e.g., different bone grafts and bone substitutes, membranes, titanium DI with surface modifications, and scaffolds loaded with drugs, osteogenic cells, or biological factors) in different studies. All the included studies reported some degree of bone regeneration based on the assessment of several biomarkers as mentioned in (Table 1) . Heterogeneity was observed among the 37 animal studies, in terms of the anatomical sites chosen to recreate an osseous defect for placement of the biomaterials. Several studies were based on a rodent model, out of which one study in mice 24 and another study in rats 25 used maxillary defects. Similarly, mandibular defects were the chosen site in sheep, 26 rabbit, 27 and rat [28] [29] [30] [31] [32] [33] models in eight of the included studies. While cranial and calvarial defects in rats were created in four of the reviewed experiments, [34] [35] [36] [37] two studies were based on calvarial 22 and spinal 38 defects in mice respectively. Among the other experimental models in rats, femur, 39-41 ulna, 42 tibia, 40, [43] [44] [45] and intramuscular sites 46 were utilized for the evaluation of bone regeneration. Nine of the reviewed studies examined the role of biomarkers, based on bone regeneration experiments in rabbit models. The osseous defect sites used in those Flow Chart 1: Search strategy and articles included in the systematic review 
Outcomes based on Translational Studies
Among the criteria evaluated for expression of bonebiomarkers in the reviewed studies based on translational animal models, the least degree of disparity was observed in terms of the types of biomaterials (bone grafts, titanium DI, 3D scaffolds, and other biological derivatives) used for bone regeneration and healing (Table 1) . Therefore, further analysis of the data was accomplished based on this aspect of the reviewed studies.
Studies using Bone-grafting Materials
Fourteen out of the 41 studies investigated the presence of bone-biomarkers during the osteoinductive and osteoconductive phases of bone healing when autogenic, allogeneic, or other alloplastic bone substitutes were placed in osseous defect sites ( TRAP-positive osteoclast-like cells 19 and osteoclastic markers cathepsin K and MMP-9 45 were reported on the surfaces of HA, β-TCP, and bioactive glass scaffolds.
Studies evaluating Bone Regeneration around Titanium DIs
The clinical success of titanium DI for esthetic and functional rehabilitation can be substantiated with evidence at the molecular level wherein biomarkers of osseointegration such as OCN and COL-1 30, 53, 59 have been illustrated during periods ranging from 4 to 8 weeks post-implant placement. In a study based on fluoride-coated titanium DI, 54 the expression of OCN, RUNX-2, and COL-1 correlated with modulatory effects of fluoride upon bone formation/resorption phases at the bone-implant biological interface. Similarly, simvastatin coating around DI placed in an osteoporotic rat model resulted in enhanced angiogenesis and osseointegration as evidenced by the increased expression of VEGF and bone ALP respectively. 44, 59 In contrast, no significant changes in biomarker expression were observed in titanium DI with surface modifications comprising of porous titanium granules, 55 roughening, 31 and TCP/HA coating. 31 Nevertheless, ALP, VEGF-R2, CD31, RUNX-2, OCN, COL-1, TRAP, IL-6, TNF-α, bone alkaline phosphatase (BALP), OPN, and OCN were commonly expressed during osseointegration, thereby indicating their significance in prognostic and clinical performance assessment. On the contrary, bone healing around DI showed an increased matrix vesicle enzyme activity (phospholipase-2) with bone bonding material like KG cera than nonbonding material like KGy-213. 43 However, enhanced or delayed mineralization correlated with the expression of ALP. In a similar study on rat maxilla, 60 increased TRAPase activity was reported for sandblasted DI with ceramic coating. Nonetheless, strontium-substituted hardystonite ceramic coating structure had the strongest expression of OCN, BMP-2, and ALP with increased osseointegration ability in comparison with other ceramic-coated DI. 56 
Studies evaluating Bone Regeneration in Three-dimensional Scaffolds
Encapsulation of bioactive molecules in three-dimensionally (3D) engineered scaffolds not only provides mechanical competence during bone regeneration, but was also coherent with elevated levels of biomarkers such as ALP, ONC, BMP, BSP, RUNX-2, and OPN. 22, 32, 35, 37, 38, 52 More specifically, calcitriol (1, 25 [OH]2D3)-loaded porous poly(D,L-lactide-co-glycolide) (PLGA) scaffolds 52 along with mesenchymal stem cells, when used for treating large bone defects, resulted in expression of COL-1 in addition to other biomarkers. Similarly, apatite-coated silk fibroin scaffolds, 38 when tested for ectopic new bone formation, revealed upregulated expression of BMP-2, OPN, OCN, and BSP. Additionally, scaffolds of extracellular matrix (ECM), 37 copolymers of poly(L-lactide-co-1,5-dioxepan-2-one), 35 premineralized silk along with BMP-2 modified bMSCs, 32 simvastatin loaded atelocollagen sponge (ACS), 49 and Nell-1 protein coat 22 led to enhanced bone formation with significant expression of ALP, OCN, BMP, BSP, IL-1, IL-6, IL-10, CD31, RUNX-2, and OPN.
Studies evaluating Bone Formation using Other Proteins and Cell Derivatives
Taut et al 25 assessed the positive therapeutic potential of sclerostin antibody (Scl-Ab) to stimulate alveolar bone regeneration in rats demonstrating concurrent expression of higher levels of OCN and procollagen type I N propeptide (PINP) in sclerostin-neutralizing monoclonal antibody (Scl-Ab) treatment groups. Under similar conditions, plasma-irradiated silk fibrin 51 and osteostatinloaded silica-based mesoporous SBA15 materials 50 grafted in the rabbit femur resulted in significantly higher expression of TGF-β, TGF-β RIII, RUNX-2, COL-1, and OCN owing to new bone formation. Remarkable bone growth was evidenced in osseous defect sites regenerated with VEGF-transfected mesenchymal stem cells and BMP-2 leading to enhanced expression of ALP, OCN, stromal cell-derived factor 1 (SDF-1), IL-6, COL-1, and CD31+. 46 Similarly, gelatin hydrogel combined with SDF-1, BMP-2, 42 and recombinant Fibroblast growth factor-2 (rhFGF2) 24 led to optimized bone formation with fibroblast growth factor (FGF)/ fibroblast growth factor receptor (FGFR) signaled bone anabolic activity and simultaneous expression of RUNX-2 and BMP-2 biomarkers.
DISCUSSION
Bone is a metabolically active tissue and its regeneration comprises of well-orchestrated series of biological events. This continuous process of bone remodeling involves formation (osteoblasts), resorption (osteoclasts), and maintenance (osteocytes) in a definable and spatial sequence affected by intracellular and extracellular signaling pathways. 61 Currently, there are a plethora of available bone augmentation strategies along with advanced cellular analytical methods for characterization of these bone-forming cells and identification of the transcriptional and translational profiles of genes and proteins encountered. 11 Hence, molecular markers of bone have gained importance in recent times to detect the dynamics of bone during various phases of regeneration. 9 In the present review, several studies demonstrated the efficacy of bone-biomarkers as prognostic indicators for the different stages of bone regeneration, in osseous defect sites, following placement of biomaterials. The commonly expressed biomarker identifiable during each stage of bone regeneration and healing when associated with biomaterials is elaborated in Table 2 .
Biomarkers of Bone Turnover
While biochemical indexes are capable of differentiating the biomarkers of bone formation and resorption, a sharp distinction may not be appreciated in clinical scenarios. This is clearly evident in the present systematic review wherein most OC fragments where detected in both matrix deposition and mineralization stages of bone healing 51, 53, 58 (Table 2) . Similarly, BMP-2 and COL-1 23, 35, 51 were expressed during early cell reactions through matrix deposition phases. Moreover, several of the reported biomarkers of bone turnover could have resulted from the nonskeletal processes and might be present in other tissues influencing their circulating levels. 33 In clinical practice, implantation of bone biomaterials within osseous defect sites is associated with high degrees of success in relation to bone regeneration and healing. 6 Nevertheless, complications arise in 5 to 10% of patients, making them liable to failed bone regeneration and impaired bone healing. 62 Such complications associated with bone biomaterials could be attributed to several factors including a characteristic of host bone, infected tissue, lack of blood supply, and disturbances to the stability of implanted biomaterials during the healing process. 63 However, the assessment of bone healing via conventional radiographic methods is subjective and is less sensitive in predicting signs of early healing complications. 8 Bone-biomarkers are the products of bone cell activity and are associated with several stages of bone healing. Consequently, bone-biomarkers have been analyzed in many of the reviewed in vivo studies for monitoring the process of bone regeneration, and provided an early diagnostic value for possible complications. 64 Bone healing in response to implanted biomaterials is expected to proceed in three overlapping stages: early bone cell reactions, bone matrix deposition, and bone mineralization. 11 The cellular interaction phase begins immediately after the implantation of biomaterials, which causes initial tissue damage and inflammation for approximately 3 to 4 days. There is evidence of formation of a fibrin-rich clot which acts as a scaffold for different molecular and cellular interactions which mediate angiogenesis. Subsequently, resorption of damaged bone by osteoclasts is observed as a key initiator for the stage of bone formation. 9 The most specific and sensitive biomarker produced by bone resorbing osteoclasts is TRAP. 65 Few other biomarkers of osteoclastic activity include the RANKL and its membrane-bound receptor RANK and OPG, wherein bone resorption is inhibited by OPG when it binds to RANKL. 66 Therefore, the balance between OPG and RANKL primarily regulates osteoclastic activity. 67 In the present systematic review, 12 studies reported that TRAP, OPG, ALP, proliferating cell nuclear antigen (PCNA), BMP-2, BMP-3, BMP-4, COL-1, OPN, RUNX-2, and CBFA-1 were associated with the early stage of cellular response to biomaterials (Table 2) . Interestingly, in 4 animal studies 24, 25, 53, 55 TRAP significantly correlated with osteoclast-like activity wherein TRAP5b was detected early in the postoperative immunoassays.
Early Bone Cell Reactions
Bone formation, when assessed at an early stage, not only has significant prognostic value, but could also facilitate confirmation of clinical success as reported by Prati et al. 18 Alkaline phosphatase is an ubiquitous, membrane-bound tetrameric enzyme, commensurate with active remodeling of bone and is validated as a predictive indicator ( 
Bone Matrix Deposition
Bone matrix deposition is evident with the proliferation and differentiation of mesenchymal stem cells into osteoprogenitor cells and subsequently into osteoblasts. Bone formation markers are derived from osteoblasts, mainly during osteoid (bone matrix) synthesis ( Table 2) . The OCN plays an important role in ECM formation and osteoid mineralization through a negative feedback mechanism. An elevated serum level of OCN has been found during periods of rapid bone turnover and it has therefore been considered a valid biomarker when bone resorption and formation are coupled. 10 Similarly, higher concentrations of OPN were observed in areas of bone formation with simultaneous recruitment and stimulation of macrophages and lymphocytes. Tera Tde et al 28 reported
intense bone metabolism associated with increased levels of OCN and OPN in healing osseous defect sites treated with e-PTFE and onlay bone graft. (Table 2) . Therefore, it would be alluring to assume impaired bone healing processes, associated with abnormal expression of these biomarkers. 3 Reis-Filho et al 33 and Kunert-Keil et al 34 reported enhanced VEGF and VEGF-R2 expression correlating with evidence of angiogenesis in the target bone. In contrast, Tanaka et al 40 reported a relatively lower expression of VEGF in new bone formation with GBR after a 10-day follow-up period. Based on the above reviewed studies, while VEGF elicited a chemo attractive effect on primary human osteoblasts and mesenchymal progenitor cells, it was significantly expressed only during the terminal stages of bone formation, preceded by an initial low level of detection. A high level of heterogeneity, possibly attributable to different experimental biomaterials, was observed in the reported expression of biomarkers associated with bone mineralization, which included PCNA, BMP, PINP, RANK, RANKL, TGF, Ki-67, Caspase-3, TUNEL and CD31.
Subject Variability
A variety of translational experimental models were used in the reviewed researches including dogs, sheep, rats, mice and rabbits, with each model considered to be ideal and simulating clinical scenarios. While, canine and sheep models exhibited maximum similarity in terms of outcomes measured, majority of the reviewed literatures were based on rodent models (rats and mice). Similarly, several types of bone defects desirable for mimicking bone regeneration in human bone were reported in the review. Interestingly, most of the studies which employed a craniofacial defect model in the mandible [27] [28] [29] 32, 33, 48, 60 and the calvarial bone, 22, 24, [34] [35] [36] reported appreciable bone formation and isolation of biomarkers for assessment. The variability of the physical and chemical characteristics of scaffolds, reported in the present review, also had a proven influence on bone regeneration and the related expression of biomarkers. For instance, subcutaneous pockets transplanted with collagen sponge and stem cells 56 reported minimal bone formation, in contrast to defect sites treated with osteoconductive scaffolds. Although the efficacy of bone regeneration can be effectively evaluated by biomarkers of bone turnover, their prognostic importance needs to be substantiated. Similarly, the quantification of bone-biomarkers for studying bone metabolism through IHC assays lacks credible evidence in large-scale population studies, in spite of being comparatively less invasive and cost-effective. 69 Nevertheless, clinical limitations in the use of biomarkers as standardized prognostic tools require continued development in identifying and quantifying more reliable biomarkers of bone healing.
70
Strengths and Limitations
The major strengths of the present literature review are the systematic search strategy and adherence to PRISMA guidelines. However, a language bias may have influenced the study results, as only English language articles were included in this review. Nevertheless, this systematic review provides valuable insights of bone-biomarkers as prognostic indicators of bone regeneration and healing. The pronounced variability and heterogeneity of bonebiomarkers make it difficult to determine their precise thresholds and hence more observational studies are needed to be carried out to identify the desirable biomarkers. Further validation of biomarkers as independent determinants of bone turn over can be established only with long-term clinical studies.
CONCLUSION
Knowledge of bone biology and their regenerative potential has greatly expanded with advances in molecular biology and research. Major limitations of the scrutinized studies were related to the biological and analytical variability. In this review, several biomarkers were confirmed to be useful for the assessment of bone regeneration and healing around biomaterials. However, there was insufficient evidence to determine whether or not bonebiomarkers can be independently utilized to monitor bone regeneration around biomaterials. Nevertheless, standardization of analytical methods and formalizing protocols toward specific dominant bone-biomarkers can facilitate future research.
